Fractyl Health (Nasdaq: GUTS) reported that Revita met its six-month co-primary endpoint in the ongoing REMAIN-1 study of post-GLP-1 weight maintenance. The randomized, double-blind, sham-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results